

RNS | 3 June 2024



**ImmuPharma PLC**  
**("ImmuPharma" or the "Company")**

**Realisation of c£1.5 million on sale of shares in Incanthera plc**

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, announces that it has realised gross proceeds of c£1.5 million on the sale of its entire holding of c9.9 million shares in Incanthera plc.

Following this transaction, ImmuPharma retains c7.3 million warrants in Incanthera plc which have an exercise price of 9.5p and exercise expiry date of 6 September 2024.

For further information please contact:

<b>ImmuPharma PLC</b> ( <a href="http://www.immupharma.com">www.immupharma.com</a> )	+44 (0) 207 206 2650
Dr Tim Franklin, COO	
Lisa Baderoon, Head of Investor Relations	+ 44 (0) 7721 413496
<b>SPARK Advisory Partners Limited (NOMAD)</b>	+44 (0) 203 368 3550
Neil Baldwin	
<b>Stanford Capital Partners (Joint Broker)</b>	+44 (0) 203 650 3650/51
Patrick Claridge, Bob Pountney	
<b>SI Capital (Joint Broker)</b>	+44 (0) 1483 413500
Nick Emerson	

**Notes to Editors**

**About ImmuPharma PLC**

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 is a first-in class autophagy immunomodulator for the treatment of Lupus and CIDP and preclinical analysis suggests P140 may have therapeutic benefit in many other autoimmune diseases that are caused by the same dysfunction in the immune system.

For additional information about ImmuPharma please visit [www.immupharma.co.uk](http://www.immupharma.co.uk)

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.